2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

2:30PM-4:00PM: Abstract Number: 2062

How Reliable Is Self-Evaluation of Symptoms of Inflammatory Back Pain By Patients?

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects

2:30PM-4:00PM: Abstract Number: 2000

Immune Response Against Â Î²2GPI Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome

Antiphospholipid Syndrome: Recent findings

2:30PM-4:00PM: Abstract Number: 2064

Increase in IL-31 Serum Level in Recent Onset Spondyloarthritis – Data from the DESIR Cohort

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects

2:30PM-4:00PM: Abstract Number: 2036

Infliximab Versus Adalimumab in Severe Uveitis: Multicenter Study from the French Uveitis Network

Miscellaneous Rheumatic and Inflammatory Diseases Oral Session II

2:30PM-4:00PM: Abstract Number: 2049

Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases

Rheumatoid Arthritis - Clinical Aspects II: Infection, Malignancy and Other Comorbidites in RA

2:30PM-4:00PM: Abstract Number: 2046

Long-Term Outcomes in Cardiac Neonatal Lupus and Associated Risk Factors for Morbidity

Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 2068

Low Complement Is Associated with SLE Classification Criteria and Organ Damage

Systemic Lupus Erythematosus - Clinical Aspects and Treatment III: Biomarkers

2:30PM-4:00PM: Abstract Number: 2052

Lymphoma in Patients with Rheumatoid Arthritis Treated with Biologic Drugs: Long-Term Follow-up of Risks and Lymphoma Subtypes

Rheumatoid Arthritis - Clinical Aspects II: Infection, Malignancy and Other Comorbidites in RA

2:30PM-4:00PM: Abstract Number: 2060

Microscopic Bowel Inflammation in Spondyloarthritis As a Baseline Predictor of Anti-TNF Response

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects

2:30PM-4:00PM: Abstract Number: 2072

Mitochondrial Reactive Oxygen Species Modulate Autoimmunity in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Modulators of Disease

2:30PM-4:00PM: Abstract Number: 2073

Mitochondrial ROS Is a Novel Regulator of Sting-Mediated Type I IFN Production By Governing Extrusion of Oxidized Mitochondrial DNA upon Neutrophil Extracellular Trap Formation.

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Modulators of Disease

2:30PM-4:00PM: Abstract Number: 2025

Modification of Structural Lesions on Magnetic Resonance Imaging By Etanercept: A 12-Week Randomized Placebo-Controlled Trial

Imaging of Rheumatic Diseases II: MRI, PET and CT

2:30PM-4:00PM: Abstract Number: 2030

MRI Changes Associated with Neurological Compromise in Acute Pyogenic Vertebral Osteomyelitis: A Retrospective Study of 121 Patients

Infection-related Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2034

Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center

Infection-related Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2021

Omega-3 Fatty Acids Are Associated with a Lower Prevalence of Autoantibody Positivity in HLA-DR Shared Epitope Positive Subjects Who Are at Increased Risk for Future RA

Epidemiology and Public Health II: RA and Lifestyle Factors

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].